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 Abstract. Much interest exists presently in development of
vectors for gene therapy of tumors based on RNA viruses
because these viruses replicate in the cytoplasm and do not
integrate into DNA. The negative stranded paramyxovirus,
Newcastle Disease Virus (NDV) from chicken has the
additional advantages of preferential replication in tumor
cells and of oncolytic and immunostimulatory properties. We
here describe the bispecific fusion protein ·HN-IL-2 which
binds to NDV, inhibits its normal cell binding property and
introduces a new binding specificity for the interleukin-2
receptor (IL-2R). We demonstrate selective gene transfer
to tumor cells expressing IL-2R via the bispecific fusion
protein when using recombinant NDV carrying as marker
gene the enhanced green fluorescence protein (NDFL-EGFP).
Hemadsorption (HA) and neuraminidase activities (NA) of
the HN protein of NDV were shown to be blocked by
·HN-IL-2 simultaneously and the absence of HA-activity of
modified NDV was confirmed in vivo. Retargeted virus-
binding to IL-2R positive tumor cells was not sufficient for
the process of cellular infection. It required in addition
membrane fusion via the viral F-protein. By modification of
recombinant NDV with a bispecific molecule, our results
demonstrate a novel and safe strategy for selective gene
transfer to targeted tumor cells.
Introduction
RNA viruses are very promising vectors for gene therapy
or for oncolytic virotherapy (1,2). Integral to the life cycle of
all RNA viruses is the formation of double-stranded RNA
(dsRNA). dsRNA activates Toll-like receptor 3 (3) and a
spectrum of cellular defence mechanisms including the
activation of RNA binding protein kinase (PKR) and the
release of interferon · and ß. Tumors are frequently defective
in their PKR signaling and interferon response pathways.
They are therefore relatively permissive for infection by RNA
viruses.
Newcastle Disease Virus (NDV), a negative-strand
RNA virus belonging to the family Paramyxoviridae, shows
tumor selective replication, which leads to tumor apoptosis
and death (4-6). Two main properties of this virus are very
interesting. First, NDV has immune stimulatory properties.
Clinical post-operative anti-tumor vaccination studies in
breast cancer (7) and glioblastoma patients (8) employing
NDV-modified autologous tumor cell vaccine (9) showed
significant improvement of patient survival (10). Secondly,
some NDV strains have oncolytic activity. This can be used
to induce tumor lysis (oncolysis) in a very efficient way. A
phase I trial of intravenous administration of PV701, an
oncolytic NDV strain, in patients with advanced solid
cancers was reported recently and a phase II clinical trial has
already started (11). Recent studies based on reverse genetics
showed that foreign genes can be cloned into this virus (12).
A recombinant NDV expressing the enhanced green fluorescent
protein (EGFP) was generated independently by two groups
by applying reverse genetics techniques (13,14). This suggests
that new therapeutic genes can also be cloned into this virus
for efficient gene expression in tumor tissues.
Two glycoproteins are expressed at the surface of NDV:
the hemagglutinin-neuraminidase (HN) protein and the
fusion (F) protein. The HN protein mediates the attachment
of NDV to cells via sialic acid-containing receptors at cell
surfaces and interacts with the F protein (15) which is
responsible for the fusion between the viral envelope and the
cellular membrane (16).
Since the sialic acid-containing receptors for NDV are
ubiquitously expressed on cell surfaces, NDV binds to every
cell, whether it is a normal or a tumor cell. Although NDV is
selectively replicating in tumor cells, its binding to normal
cells might compromise its therapeutic effect and cause side-
effects when administered systemically in vivo. To avoid the
binding of NDV to normal cells and to selectively target it
to tumor cells, we modified the virus by adding a bispecific
fusion protein to it. This bispecific protein (named ·HN-IL-2)
contains a single-chain antibody (scFv) specific for the HN
protein linked to the cytokine human interleukin-2. ·HN-
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IL-2 blocks the native cell binding activity of NDV and
simultaneously provides a new binding specificity for the
interleukin-2 receptor (IL-2R) (here used as tumor target).
Using IL-2R- cells (Jurkat cells) and IL-2R+ cells (MT-2
cells), we showed previously in vitro that the modification
of NDV with ·HN-IL-2 blocks NDV binding to Jurkat cells
and redirects it to bind to MT-2 cells (17). In this study, we
investigated the mechanism of virus entrance, the safety issues
of such modified viruses and its efficiency for retargeted
gene delivery in vivo.
Materials and methods
Cells. The human Jurkat CD3 cell line that was sorted from
Jurkat cells for CD3-positivity was grown in RPMI-1640
medium supplemented with 5% inactivated foetal calf serum
(FCS), 2 mM L-glutamine, 2% HEPES and 100 U/ml
penicillin-100 µg/ml streptomycin. MT-2, a HTLV-1 trans-
formed T cell line, was kindly provided by Dr Masahiko
Makino (Department of Microbiology, National Institute of
Infectious Disease, Tokyo, Japan). MT-2 cells were propagated
in the same RPMI-1640 medium supplemented with 10%
FCS. All reagents were purchased from Gibco Life Techno-
logies (Karlsruhe, Germany). Both cell lines were maintained
at 37˚C in a humidified atmosphere of 5% CO2.
Antibodies. Mouse anti-HN monoclonal antibody (HN.B
mAb, IgG 2a) and mouse anti-F mAb lcii (IgG1), kindly
provided by Dr R.M. Iorio (Department of Molecular Genetics
and Microbiology, University of Massachusetts, Medical
School MA, USA) was used in flow cytometry to detect
NDV viral antigens on host cell surfaces. Goat F(ab')2 anti-
mouse Ig-RPE was obtained from Southern Biotechnology
Associates, Inc. (Birmingham, USA). Biotin labelled anti-
HLA-A, B, C mAb (clone: W6/32) was kindly provided by
Dr Gerd Moldenhauer (Division of Molecular Immunology,
German Cancer Research Center, Heidelberg, Germany).
Streptavidin-Alexa Fluor 647 were from Molecular Probes
(Molecular Probes, Leiden, The Netherlands). 
Recombinant NDV. The recombinant NDFL-EGFP was
derived genetically from non-lytic strain NDV-LaSota by
reverse genetics as described previously (18). The parent
recombinant NDFL+ virus was generated from cDNA
clone of NDV-LaSota (18). The virus was propagated in
embryonated chicken eggs, harvested from the allantoic fluid,
purified by ultracentrifugation, and cryopreserved in aliquots
at -70˚C. The virus was quantified by a hemagglutination assay.
One hemagglutination unit (HU) is defined as the smallest virus
concentration leading to visible sheep erythrocyte agglutination.
NDV was UV inactivated for some experiments as described
previously (19).
Modification of NDV with bispecific fusion protein 
 
·HN-IL-2.
Modification of NDV was performed by incubation of
NDV with appropriate amounts of the recombinant protein
·HN-IL-2 for 1 h on ice. This protein was constructed by
fusion of a single-chain antibody cloned from a neutralizing
HN specific hybridoma linked to the human cytokine IL-2 as
described previously (17).
NDV binding and infection of tumor cells in vitro. Cell
suspensions were washed twice with FCS-free RPMI-1640
medium and 1x107 cells were incubated with 100 HU (or 10
HU) of NDV or the same doses of modified NDV/·HN-IL-2
in a final volume of 1 ml for 1 h at 37˚C in a CO2 incubator.
During the incubation, cells were shaken every 15 min.
The cells were then washed twice and either stained with
antibodies and analyzed by FACS to measure the bound virus
or the cells were further cultured for 24 h to allow for viral
replication. Viral replication was then evaluated as EGFP
fluorescence by flow cytometry.
Flow cytometry. Cells, 5x105/sample, were used for analysis
by a FACScan flow cytometer (Becton Dickinson,
Heidelberg, Germany). All antibodies were diluted in FACS
buffer (PBS containing 5% FCS and 0.1% NaN3). Cells were
washed twice with FACS buffer and then incubated with the
first antibody. Subsequently the cells were washed and
incubated with goat F(ab')2 anti-mouse Ig-RPE for 30 min on
ice in the dark. In some experiments, NDFL-EGFP was used
to check for viral replication. Replication of NDFL-EGFP in
host cells leads to the expression of EGFP which has a high
level of fluorescence that can be measured directly by flow
cytometry without antibody staining. All FACS data were
analyzed with CELLQuest software (Becton Dickinson,
Heidelberg, Germany).
Treatment of cells with MG132. MT-2 cells (1x106) were
washed twice with FCS-free RPMI-1640 medium and then
incubated with MG132 (Calbiochem, Germany) at a final
concentration of 50 µM for 1 h at 37˚C. Without washing,
the treated cells were infected by NDV using the standard
protocol as described above.
Determination of hemadsorption (HA) and neuraminidase
(NA) activities. The HA activity of HN proteins of NDV
was determined by testing their ability to adsorb human
erythrocytes. Human erythrocytes were isolated from buffy
coat by centrifugating at 600 x g and then washed with 3-fold
volume of isotonic PBS. Erythrocytes (1x106) were co-
incubated with NDV for 1 h using the above described
protocol and analysed with flow cytometry. NA activity of
HN proteins of NDV was also determined by flow cyto-
metry. Briefly, 1x106 erythrocytes were co-incubated with
NDV for 1 h at 37˚C. After 2 washes in PBS, the erythrocytes
were incubated with 3.1 µg/ml peanut agglutinin (PNA)-
FITC (Sigma, Munich, Germany) for 30 min at room
temperature and then analysed by FACS analysis.
Ex vivo modification in vivo. Pathogen-free DBA/2 mice
were obtained from Charles River GmbH (Wiga, Germany)
and kept under pathogen-free conditions at the DKFZ animal
facilities (Heidelberg, Germany). All procedures involving
mice was approved by the Animal Care and Use Committee
of German Cancer Research Center. Mice received whole
body irradiation at 4.5 Gy 1 day before i.p. injection of
1x107 human Jurkat or MT-2 cells which were infected ex vivo
either with 100 HU NDFL-EGFP or modified NDFL-EGFP/
·HN-IL-2 for 1h at 37˚C. For the negative controls, NDV
was replaced by PBS. After 24 h, cells in the mouse peritoneal
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cavity were harvested by lavage technique using ice-cold
PBS containing 5% FCS. Human cells were differentiated
from native mouse cells by two step staining with biotin-
anti-HLA-A, B, C mAb and then with streptavidin-Alexa
Fluor 647. Viral replication in HLA-I-positive cell population
was evaluated by determination of the EGFP fluorescence
with FACS analysis.
Results
Correlation between virus replication and transgene
expression. Since viral replication is associated with
amplification of the two viral surface proteins (HN and F),
NDV replication can be evaluated quantitatively by FACS
analysis of the infected live cells using anti-HN or anti-F
antibodies (Fig. 1A). Twenty-three hours after infection with
live virus or after co-incubation with UV-inactivated virus,
the human MT-2 leukemia cells were stained with anti-HN
mAb. We observed two cell populations: one with high viral
antigen density (HAD) and another with low antigen density
(LAD). HAD cells were seen only after infection with
replication competent live virus and represent cells that had
undergone high-copy virus replication. When using UV-
inactivated virus, only cell surface bound virus was seen (LAD
cells) and no viral replication could be detected (Fig. 1B). To
determine whether the fluorescence signal induced by the
expression of a transgene (EGFP) inserted into the virus
correlates with virus replication, MT-2 cells were also infected
with NDV carrying the EGFP transgene (NDFL-EGFP) or
the UV-inactivated NDFL-EGFP. Cells with increased EGFP
fluorescence intensity were seen only in tumor cells infected
with replication-competent live NDFL-EGFP (Fig. 1C).
The results demonstrate that high expression of the EGFP
gene is correlated with virus replication so that high EGFP
fluorescence can serve as surrogate marker for virus replication.
Quantitative and kinetic aspects of NDV modification by
·HN-IL-2. To test the effect of the bispecific fusion protein
·HN-IL-2 on the binding specificity of NDV, either 10 HU
or 100 HU NDFL-EGFP was pre-incubated with different
amounts of ·HN-IL-2 for 1 h on ice. Then this modified
virus (NDFL-EGFP/·HN-IL-2) was co-incubated with IL-2R-
(Jurkat) and IL-2R+ (MT-2) cells for 1 h at 37˚C. At both
virus concentrations we saw a retargeted binding of the NDFL-
EGFP/·HN-IL-2 to the MT-2 cells (Fig. 2). The binding of
NDFL-EGFP/·HN-IL-2 to Jurkat cells was neutralized to
≥99% at concentrations of ·HN-IL-2 of 10 µg/ml for 10 HU
virus (Fig. 2A, left) and of 20 µg/ml for 100 HU virus (Fig. 2A,
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Figure 1. Quantification of NDV binding and replication. MT-2 cells (106) were incubated with 10 HU of NDFL+ (A), UV-inactivated NDFL+ (B), NDFL-
EGFP (C), or UV-inactivated NDFL-EGFP (D) for 1 h at 37˚C. After washing away unbound virus, cells were examined directly (heavy grey peak), 15 h
(light grey peak) or 23 h (bold black line) after incubation. Cells of (A) and (B) were subjected to FACS analysis after staining with HN.B mAb and goat anti-
mouse F(ab')2-PE. Cells of (C) and (D) were analyzed for EGFP fluorescence as FL1 by flow cytometry. Dotted lines represent infected cells that were stained
with only second Ab (A and B) or cells that were incubated with FCS-free medium (C and D).
right). A 2.2- and 1.1-fold higher binding of the modified
virus was seen to MT-2 cells in comparison to the native
virus when using 10 HU or 100 HU, respectively.
We next tested EGFP gene transfer via recombinant
NDFL-EGFP/·HN-IL-2. EGFP fluorescence was analysed
by flow cytometry at different times after infection of Jurkat
and MT-2 cells. Maximal retargeted gene transfer in MT-2
cells was observed at 36 h and 24 h post-infection when
using 10 HU (Fig. 2B, left) and 100 HU (Fig. 2B, right) of
NDFL-EGFP/·HN-IL-2, respectively. At these two time-
points, relative retargeted EGFP expression was observed in
43 and 74% of the MT-2 cells infected with a virus load of
10 HU and 100 HU respectively. In contrast, <10% of the
IL-2R negative Jurkat cells expressed EGFP, irrespective of
the virus dose used.
Role of the F protein for retargeted virus entry. To study
possible mechanisms of cell entry of the modified virus, we
first used the proteasome inhibitor MG132. When added at a
concentration of 50 µM to the MT-2 cells during infection,
we observed no effect on either native NDV infection nor
on retargeted virus entry (Fig. 3A). This suggests that the
retargeted virus entry to IL-2R+ cells is not mediated through
internalization via the IL-2 receptor. We further tested the
effect of a mAb specific for the F protein under conditions of
retargeted virus entry. As shown in Fig. 3B, retargeted EGFP
expression was strongly inhibited by the anti-F mAb in a
dose-dependent manner. The data demonstrate: i) that
retargeted virus binding to the IL-2R is not sufficient for the
process of cellular infection; and ii) that membrane fusion
involving the F protein plays a role for retargeted virus entry.
Stability of modified NDFL-EGFP/·HN-IL-2 in vitro. To test
for the stability of native virus and of the complex between
NDV and ·HN-IL-2, aliquots of NDFL-EGFP or NDFL-
EGFP/·HN-IL-2 were incubated in serum-free RPMI-1640
medium at 37˚C for different time periods (4-76 h). After
each time-point, aliquots were kept at -70˚C until they were
added to Jurkat and MT-2 cells. As can be seen from Fig. 4A,
more than 50% of virus activity of NDFL-EGFP was lost
after 24-h incubation at 37˚C. After 3 days at 37˚C, viral
activity of NDFL-EGFP was lost completely. The virus activity
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Figure 2. Quantitative and kinetic aspects of NDV modification by ·HN-IL-2. (A), 10 HU (left) or 100 HU per 107 cells (right) of NDFL-EGFP were pre-
incubated with different amounts of ·HN-IL-2 for 1 h on ice and then further incubated with 106 Jurkat or MT-2 cells for 1 h at 37˚C. After unbound virus
was washed away, the cells were stained with anti-F mAb and goat anti-mouse F(ab')2-PE before FACS analysis. (B), 10 HU per 107 cells of NDFL-
EGFP/·HN-IL-2 were pre-incubated with 9.2 µg/ml of ·HN-IL-2 for 1 h on ice (left), or 100 HU per 107 cells of NDFL-EGFP were modified with 12 µg/ml
·HN-IL-2 (right). The modified viruses were then further incubated with 106 Jurkat or MT-2 cells for 1 h at 37˚C. After unbound virus was washed away the
cells were further cultured. At different time-points after infection, aliquots of infected cells were analyzed by FACS to detect the EGFP fluorescence. The
percentage of retargeted EGFP expression was calculated as the ratio of the percentage of positive cells after infection with the modified virus to the percentage
of positive cells after infection with the native virus.
of the modified NDFL-EGFP/·HN-IL-2 in IL-2R+ MT-2
cells decreased more slowly compared to native NDFL-EGFP
(Fig. 4B). Thus, the bispecific fusion protein ·HN-IL-2 did
not dissociate from the virus particles, indicating a high
stability in vitro of the complex between NDV and ·HN-
IL-2.
Inhibition of HA and NA activities of NDV by ·HN-IL-2 in
vitro and in vivo. HA activity of native and modified NDV
was determined by incubating the viruses with erythrocytes
followed by staining with the F-specific mAb and flow cyto-
metry analysis. NA activity was quantified by staining the
co-incubated erythrocytes with PNA-FITC which binds to
the cleaved sialic acid receptor sites. Fig. 5A shows that
·HN-IL-2 inhibited both HA and NA activities in a dose-
dependent manner. The 50% inhibitory concentration of
·HN-IL-2 was 0.4 µg/ml and 1.5 µg/ml for NA and HA
activities, respectively. These results demonstrate that
·HN-IL-2 simultaneously blocks HA and NA activities of
the HN protein of NDV.
The inhibition of HA activity of NDV by ·HN-IL-2 was
also tested in vivo using the recombinant strain NDFL-EGFP.
DBA/2 mice were injected i.v. with 5000 HU of either
NDFL-EGFP or NDFL-EGFP/·HN-IL-2. The mice were
bled after 1 h or 24 h and the erythrocytes stained with
HN-specific mAb. As can be seen in Fig. 5B, 22% of mouse
erythrocytes bound the native virus after 1 h. At 24 h, 10% of
erythrocytes still had the native virus at their cell surface.
Following injection of the modified virus we did not detect
any virus bound to the erythrocytes.
Retargeted gene expression in vivo. To evaluate retargeted gene
transfer in vivo, human MT-2 or Jurkat cells were infected
either with native or modified NDV ex vivo and then given i.p.
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Figure 3. Mechanism of infection by the modified virus NDFL-EGFP/·HN-
IL-2. (A), Effect of MG132 on the native NDV infection and the retargeted
EGFP expression. MT-2 cells (106) in serum-free medium were incubated
with MG132 at a final concentration of 50 µM or an equivalent volume of
DMSO for 1 h at 37˚C. The treated cells were then infected by NDFL-EGFP
or modified NDFL-EGFP/·HN-IL-2 for 24 h at 37˚C. EGFP fluorescence was
detected by FACS analysis. (B), Role of the F protein of NDV. To block the
F protein of NDV, 10 HU of NDFL-EGFP were pre-incubated with different
amounts of anti-F mAb before being further incubated with 12 µg/ml of ·HN-
IL-2 (ƒ) or PBS (∫) for 1 h on ice. This double modified virus was added to
106 MT-2 cells for 24 h and the EGFP signal was analyzed by FACS. The
percentage of inhibition was calculated as the ratio of the percentage of
positive cells after infection with the double modified NDFL-EGFP/anti-F
mAb/·HN-IL-2 (or PBS) and the percentage of positive cells after infection
with the native virus.
Figure 4. Stability of the modified NDFL-EGFP/·HN-IL-2 in vitro. Aliquots
of NDFL-EGFP (ƒ) and modified NDFL-EGFP/·HN-IL-2 (∫) in the
presence of serum-free RPMI-1640 medium were stored at 37˚C for 0, 4, 20,
24, 48 or 76 h. After each time-point, aliquots of virus were kept at -70˚C until
they were added to 106 Jurkat (A) and 106 MT-2 (B) cells for 24 h at 37˚C.
The percentage of EGFP-expressing cells was determined by FACS analysis.
to DBA/2 mice which were Á-irradiated with 4.5 Gy one day
before injection. After 24 h, peritoneal cells were harvested and
the human MT-2 and Jurkat cells were stained with anti-HLA-
A,B,C mAb to differentiate them from mouse cells. Then
EGFP fluorescence was analyzed by FACS analysis. As shown
in Fig. 6, 7.0% of MT-2 cells and 0.0% of Jurkat cells were
infected by NDFL-EGFP/·HN-IL-2. In contrast, using native
NDFL-EGFP there was a similar percentage of cells (31-34%)
infected when using the two tumor lines.
Interestingly, MT-2 cells when infected with both native
and modified NDV upregulated in vivo the expression of HLA
class I molecules in comparison to cells treated with PBS
instead of virus. As can be seen from the mean fluorescence
intensities (Table I), there was a connection between virus
replication and HLA class I upregulation. There was no
upregulation in Jurkat cells treated with modified virus in
which case normal infectivity was blocked.
Discussion
We here demonstrate that NDV, when modified by the
bispecific fusion protein ·HN-IL-2, is an efficient vector for
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Figure 5. Inhibition of HA and NA activities of NDV by ·HN-IL-2. (A), 106 human erythrocytes isolated from buffy coat were incubated with 10 HU NDFL-
EGFP or same dose of NDFL-EGFP which was modified with different amounts of ·HN-IL-2 for 1 h at 37˚C. After unbound virus was washed away, the
cells were stained with anti-F mAb and goat anti-mouse F(ab')2-PE (∫) or with PNA-FITC (ƒ) before FACS analysis. (B), DBA/2 mice were injected i.v. with
5000 HU of either native NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2. At 1 h and 24 h-post injection, the mice were bled and 106 isolated erythrocytes
were stained with HN.B mAb and goat anti-mouse F(ab')2-PE before FACS analysis.
selective gene transfer into tumor cells. Vector delivery
appears to be specific both in vitro and in vivo for cell lines
expressing the defined targeted cell surface molecule.
In this study, we selected the IL-2R as a potential tumor
target molecule. Adult T-cell leukemia (ATL) cell lines,
which are infected with human T-cell leukemia virus-I
(HTLV-I), uniformly express large amounts of IL-2R·
chains (20). The observation that IL-2R· is not expressed by
resting normal cells, but is expressed by a proportion of
the abnormal cells in certain forms of lymphoid neoplasia,
provides the rationale for the use of the IL-2R· as a target
(21,22). MT-2, a HTLV-1 transformed T cell line, showing
high expression of IL-2R· (20) was used for the retargeting
experiments. Jurkat CD3 cells, which do not show any IL-2R·
after staining with human CD25 mAb, were used as negative
controls. Using this system, we observed a significant effect
of ·HN-IL-2 on the tropism of NDV infection. The bispecific
molecule abolished the viral native binding capacity, and it
provided simultaneously a novel high-affinity binding site.
Several approaches have been reported to improve the
targeting capacity of virus vectors. Measles virus (MV),
another negative-strand RNA virus of the family Para-
myxoviridae, which binds to its native receptor CD46 was
genetically modified to target additional novel receptors [e.g.
epidermal growth factor (23), CD20 (24), CD38 (25), and
human carcinoembryonic antigen (26)] on tumor cells by
fusing antigen specific scFv antibody binding sites to the
C-terminus of the hemagglutinin of MV. A limitation of this
strategy was that the native binding site was not totally
abolished. Bispecific reagents have been used in different virus
vectors, such as adenovirus (Ad) (27), and adeno-associated
virus (AAV) (28) to limit gene transfer to the target cells. By
employing a bispecific scFv Ab directed against the renal cell
carcinoma (RCC)-associated G250 protein and the Ad fiber
knob domain, Jongmans et al showed the retargeting of a
recombinant Ad to RCC cells with the highly tumor-specific
G250 protein as the target (29).
During normal infection of a cell by NDV, interactions
between the HN and F proteins in a virus type-specific
manner is crucial for efficient membrane fusion and infection.
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Figure 6. In vivo retargeted gene transfer of EGFP via NDFL-EGFP by ·HN-IL-2 to tumor cells after ex vivo infection. DBA/2 mice were given whole body
irradiation with 4.5 Gy 1 day before i.p. injection of 107 human MT-2 or Jurkat cells which were infected ex vivo either with 100 HU NDFL-EGFP or modified
NDFL-EGFP/·HN-IL-2 for 1 h at 37˚C. PBS was used as negative control instead of NDV. After 24 h, cells from the mouse peritoneal cavity were harvested by
lavage technique using ice-cold PBS containing 5% FCS. Human cells were differentiated from native mouse cells by staining with biotin-anti-HLA-A, B, C
mAb and streptavidin-Alexa Fluor 647. Viral replication in the HLA class I-positive cell population was evaluated by determination of the EGFP fluorescence
by FACS analysis.
Table I. In situ HLA class I upregulation on human tumor




MT-2 cell 1455 2311 620
Jurkat cells 673 981 658
–––––––––––––––––––––––––––––––––––––––––––––––––
For experimental details see legend to Fig. 6. The values represent
mean fluorescence intensity after staining for expression of HLA-
A,B,C molecules at the cell surface followed by FACS analysis.
–––––––––––––––––––––––––––––––––––––––––––––––––
Binding of the HN protein to its sialic acid-containing cellular
receptor is thought to induce a conformational change near
the hydrophobic surface of the HN protein thereby triggering
the activation of the F protein, which initiates membrane
fusion (30,31). Being aware of this, we were curious to find out
whether there was also a role for the F protein under our
conditions of retargeted virus entry. Alternatively, virus entry
could be mediated through internalization of the targeted IL-2R
complex. Yu and Malek found that the proteasome inhibitor
MG132 at a final concentration of 50 µM impaired the
internalization of IL-2-IL-2R and prevented the lysosomal
degradation of IL-2 (32). We showed before that retargeted
gene delivery by the modified virus in IL-2R+ MT-2 cells is
blocked by human recombinant IL-2. This corroborates the
specificity of retargeted binding via IL-2R (17). Here we
demonstrate that retargeted virus entry could be blocked by
anti-F mAb but not by the proteasome inhibitor MG132. This
suggests that not only binding of NDV/·HN-IL-2 to the IL-2R
is required but also fusion via the F protein to facilitate virus
entry.
We further demonstrate that the modification of NDV
with bispecific protein could simultaneously block the
hemadsorption and neuraminidase activities of the HN
protein. The HN protein of NDV is a multifunctional enzyme
with three known functions: i) HA activity recognizes sialic
acid-containing glycoproteins on host cell surfaces; ii) NA
activity cleaves sialic acid residues from newly formed
glycoproteins inside the host cell to prevent self-aggregation
and ensure proper virus budding and iii) a fusion promoting
activity facilitates interaction between HN and F (31,33).
Crystal structure analysis confirmed that there is only one
site on the HN protein with dual functions, the HA and NA
activities (33). By possessing these activities, NDV can cause
hemagglutination of red blood cells (35-40). The addition of
·HN-IL-2 to NDV is shown here to prevent both HA and NA
activities simultaneously.
One of the advantages of the modified NDV is the
prevention of aggregation of red blood cells upon systemic
administration, suggesting less side-effects. By blocking the
HN protein with ·HN-IL-2, the HA and NA activities of native
NDV were abolished completely with human erythrocytes
(data shown) as well as with mouse or sheep erythrocytes
(data not shown). ·HN-IL-2 also inhibited the hemolytic
activity induced by the virulent strain NDV-Italien. The
decrease in the hemolytic activity was directly proportional
to the ·HN-IL-2 concentration (data not shown). Erythrocyte
aggregation is one of the main determinants influencing
blood circulation at low shear rates by increasing blood
viscosity and inducing ‘sludging’ in the capillary (41). An
increase in erythrocyte aggregation was found to be associated
with cardiovascular risk factors such as hypertension (42)
and hyperlipoproteinemia (43). A phase I trial of intravenous
administration of the oncolytic NDV (PV701) showed that
hypertension was observed in 5/7 patients. In their study this
was suggestive of a vasospasm effect, but no ECG changes
were observed. Prophylaxis with antihistamines was found to
be ineffective (44). Based on our present study, erythrocyte
aggregation by NDV PV701 probably contributes to the
hypertension. According to our results, a modified NDV
appears to be safer for systemic administration.
In order to extend retargeted gene expression studies to
in vivo conditions, human MT-2 or Jurkat cells were co-
incubated ex vivo for 1 h by NDFL-EGFP/·HN-IL-2. These
cells were then injected into the peritoneal cavity of mice.
Retargeted EGFP fluorescence was observed in MT-2 cells,
but not in Jurkat cells. The efficiency of virus infection
was, however, reduced compared to the native virus. Previous
in vitro studies demonstrated that human tumor cell
modification by NDV leads to upregulation of HLA class I
and cell adhesion molecules, induction of IFN-·, -ß and
chemokines and, finally to apoptosis (19). In this study we
verified the upregulation of HLA class I molecules upon
NDV infection in vivo. Hence, by retargeting NDV with a
therapeutic gene to the site of a tumor or its metastases,
synergistic therapeutic effects can be expected from the
therapeutic gene product and from the immunostimulatory
properties of this virus.
In conclusion, we demonstrate that modification of
recombinant NDV with a bispecific fusion protein can
abolish side-effects of the virus on erythrocytes and at the
same time redirect the virus to a new tumor target. Significant
gene transfer is shown in vitro and in vivo in retargeted
tumors.
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